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Background: HPV infection is a worldwide problem strictly linked to the development of cervical cancer.
Persistence of the infection is one of the main factors responsible for the invasive progression and women
diagnosed with intraepithelial squamous lesions are referred for further assessment and surgical treatments which
are prone to complications. Despite this, there are several reports on the spontaneous regression of the infection.
This study was carried out to evaluate the effectiveness of a long term polyhexamethylene biguanide (PHMB)-based
local treatment in improving the viral clearance, reducing the time exposure to the infection and avoiding the
complications associated with the invasive treatments currently available.
Method: 100 women diagnosed with HPV infection were randomly assigned to receive six months of treatment
with a PHMB-based gynecological solution (MonoginW, Lo.Li. Pharma, Rome - Italy) or to remain untreated for the
same period of time.
Results: A greater number of patients, who received the treatment were cleared of the infection at the two time
points of the study (three and six months) compared to that of the control group. A significant difference in the
regression rate (90% Monogin group vs 70% control group) was observed at the end of the study highlighting the
time-dependent ability of PHMB to interact with the infection progression.
Conclusions: The topic treatment with PHMB is a preliminary safe and promising approach for patients with
detected HPV infection increasing the chance of clearance and avoiding the use of invasive treatments when not
strictly necessary.
Trial registration: ClinicalTrials.gov Identifier NCT01571141
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Human papilloma virus (HPV) is a worldwide genital in-
fection and it is considered the most common cause of
sexual transmitted infections (STIs). It is possible to
count more than 100 HPV types known to infect
humans and among these 13 have been classified as
“high-risk” (HR) by the WHO International Agency for
Research on Cancer. In particular, types 16 and 18 have
been linked to more than 70% of cervical cancer [1,2].* Correspondence: antonino.gentile3@tin.it
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reproduction in any medium, provided the orCurrently, the only tool that medicine has to identify
the HPV infection early is cervical cancer cytological
screening and women diagnosed with high-grade intrae-
pithelial squamous lesions (H-SIL) are referred for fur-
ther assessment with colposcopy and biopsy to prevent
the invasive progression.
On the other hand, a follow up check is carried out on
women with detected low-grade intraepithelial squa-
mous lesions (L-SIL) due the increased risk of develop-
ing H-SIL [3,4].
HPV transmission depends on several factors such as
the infectivity of the organisms, sexual behavior and the
effectiveness of control interventions.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(cytotoxic, physically ablative, excisional, and immuno-
modulatory therapies for genital warts) may reduce the
symptoms but are relatively ineffective in eradicating the
infection and/or decreasing the likelihood of disease
transmission [5].
So far, the surgical removal of the lesions followed by
the local application of therapeutic agents is considered
the most effective therapy, avoiding the progression to
pre-cancer lesions which are more likely to occur when
the infection persists over time. Despite this, all the inva-
sive treatments currently performed (cryotherapy, surgi-
cal excision, electrosurgery or laser vaporization with
CO2) are associated with several complications including
cervical stenosis, bleeding and infection. Furthermore,
there are a few reports on the spontaneous regression of
low- and medium-grade lesions which offer the possibil-
ity to avoid the treatment [6]. In order to take full ad-
vantage of it and to increase the regression rate, the
identification of a non-invasive therapeutic agent able to
interact with the HPV infection is strongly warranted.
The clinical application of polyhexamethylene biguan-
ide (PHMB)-based compounds has been mainly reported
for the treatment of bacterial vaginosis and wounds.
PHMB is a strong base which interacts with acidic phos-
pholipids leading to increased fluidity and permeability
of the bacterial cellular membrane and consequently to
the death of the pathogen. Neutral phospholipids are not
affected by PHMB thus justifying the low toxicity against
the human cells [7]. Furthermore, the antiviral activity of
PHMB and other biguanides has been also reported
[8,9].
In this study, a long-term treatment with a PHMB-
based gynecological solution (MonoginW, Lo.Li. Pharma,
Rome - Italy) has been performed on patients diagnosed
with HPV infection to evaluate the effectiveness in in-
creasing the spontaneous regression rate.
Methods
From January to December 2010, 100 women were en-
rolled at the “Consultorio Familiare Terme Vigliatore, A.
S.P. 5” of Messina, Italy. Subjects aged between 30 and
45 years and diagnosed with the HPV infection after the
pathologic Pap smear (ASC-H, L-SIL and H-SIL), a posi-
tive “high risk” HPV DNA test and a positive colposcopy
examination (abnormal transformation grade 1 or 2)
were included in the study. Exclusion criteria were wart
therapy in the previous six months, pregnancy, invasive
disease, immunosuppression and previous HPV vaccin-
ation. All the patients gave their written informed con-
sent before entering the study which was approved by
the SIFIOG (Italian Society of Phototherapy and Dietary
Supplements in Obstetrics and Gynecology) ethical
committee.Protocol
This hyphotesis-generating study was performed to in-
vestigate whether a long treatment with a PHMB based
gynecological solution, which has been reported to have
biocidal activity, may improve the regression rate of
HPV infection.
A pre-enrolment screening questionnaire was used to
record the social and medical history of the patients
and no differences were observed. Patients were ran-
domly assigned to two groups using a computer based
program.
Group A consisted of 50 women who received treatment
with a polyhexamethylenbiguanide (PHMB) gynecological
solution (MonoginW, Lo.Li. Pharma, Rome - Italy) every
three days for fifteen days and then every fifteen days for
the subsequent six months. MonoginW is a mono-dose
gynecological liquid-gel constituted by PHMB, EDTA, gly-
cerol, hydroxymethyl cellulose, potassium chloride, lactic
acid and water; the administration did not require any par-
ticular procedure and it was self-administered by the
patients before bedtime, following the information reported
in the leaflet.
Group B, consisting of other 50 women, did not re-
ceive any treatment and was considered as control
group.
Evaluation of PHMB effectiveness in increasing the re-
gression rate of the infection was performed by taking
cervical scrapings for HPV analysis, Pap smears and a
colposcopy examination. This procedure was performed
at the enrollment and repeated after three (T1) and six
months (T2), following the initial diagnosis of HPV
infection.HPV analysis
HPV detection was performed using the HPV high-risk
test (HC2, Qiagen, Baltimore, USA) which detects 13
high risk oncogenic HPV types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59 and 68). An HPV sample was consid-
ered positive according to the Food Drug Administration
(FDA) guidelines and the standard 1.0 pg HPVDNA ml-1
threshold was adopted.
Cervical scrape samples were collected in ThinPrep
vials containing PreservCyt (Cytyc Corp., Marlborough,
USA) transport medium or in Specimens Transport
Medium (STM) (DNAPAP cervical sampler, Qiagen,
Gaithersburg, USA) and the results were classified fol-
lowing the 2001 Bethesda System [10].
Colposcopy examination was performed following the
general guidelines described elsewhere [11].Statistical analysis
To compare the regression rate of HPV infection in the
two groups the Fischer’s exact test has been used and
Table 2 Number of patients with or without HPV
infection at T2
Group (n =50) T2
Infection free Infection RR (CI95)
MonoginW 45* 5 1.29 (1.05-1.58)
Control 35 15
*P value = 0.023, respect to the control group at the T2.
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The analysis has been conducted using GraphPad
Prism software (Graph Pad Software, Inc., La Jolla USA).
Results
All the enrolled patients completed the study. The evalu-
ation of Pap smear, HPV DNA test and colposcopy were
repeated after three months and at the end of the study
and the infection was considered cleared when all the
features were found negative.
Results have shown that after three months (T1) a re-
gression rate of the infection was observed in the 66%
(33/50 patients) of the patients treated with MonoginW
gynaecological solution compared to the 56% (28/50
patients) of the control group (Table 1). The difference
between the two groups did not reach statistical differ-
ence (RR 1.18, CI95 0.86-1.62). At the end of the study
(T2) a reduction of the number of HPV positive patients
was still observed in both groups with a significant in-
crement of the regression rate in the patients who
received the treatment (90% MonoginW vs 70% control
group, P value = 0.023; RR 1.29, CI95 1.05-1.58; Table 2).
All the treated patients were asked about adverse effects
and no side effects related to the long term use of the
PHMB-based gynaecological solution (MonoginW) were
reported.
At the end of the study, due to the persistence of posi-
tive colposcopy and positive Pap smear and HPV DNA
test, five patients in the Monogin group and fifteen in
control group were successively treated according to the
national guidelines.
Discussion
In this randomized trial we have shown that six months
treatment with a PHMB-based gynaecological solution
(MonoginW, Lo.Li. Pharma, Rome - Italy) increases the
regression rate of the HPV infection. In particular, the
treatment already exerts beneficial effects at three
months compared to an untreated control group.
The presence of cervical HPV DNA is often associated
with cytological and histologic changes of cervical
intraepithelial neoplasia (CIN) [12]. Despite this, there
are a few reports showing a spontaneous regression of a
number of low- and medium-grade lesions and the ma-
jority of women clear the virus or suppress it to levelsTable 1 Number of patients with or without HPV
infection at T1
Group (n =50) T1
Infection free Infection RR (CI95)
MonoginW 33 17 1.18 (0.86-1.62)
Control 28 22not associated with significant cervical dysplasia. Gloria
Ho et al. reported that the median duration of HPV in-
fection is 8 months and that 70% of women clear the in-
fection after 12 months [13].
On the other hand, since the time exposure with high
risk HPV types is directly connected with the risk of de-
velopment of cervical cancer, the development of non-
invasive therapeutic agents able to improve the viral
clearance is necessary.
Up to now, only a few therapeutic agents able to inter-
act with the infective process are known and currently
prescribed. In particular, Imiquimod (AldaraW) which
entered in the market in 1997, is an immune response
modifier which induces the activation of congenital and
acquired T-cell immunity stimulating the production of
host interferon and other endogenous cytokines with
antiviral properties. Another therapy currently available
is represented by interferon (IFN) which are endogenous
intracellular proteins possessing not only anti-cancer,
but also antiviral immunomodulating effects [13]. Never-
theless, several side effects and complications are asso-
ciated with the administration of these agents and the
search for new safe and effective anti-HPV compounds
is still warranted.
PHMB is a well-known antimicrobial agent and
a number of scientific evidences on its antiviral activity
have also been reported. Specific activity against cell-free
viruses may be attributable to interactions between
PHMB and components of the virion membrane. It has
been suggested that PHMB is effective against HIV-1
in-vitro since the cellular infection is mediated by
components in both the cellular membrane and the viral
envelope. These interactions cause a decrease of
the virulence disrupting the integrity of the viral
particle [14].
Further studies confirmed the antiviral activity
of biguanide-based molecules suggesting a specific
mechanism that has a co-receptor dependency [9]. Add-
itional studies also reported the in-vitro activity against
HSV-1, HSV-2 and VZV at the PHMB concentration of
0.01% [8].
Marelli et al. first investigated the clinical effectiveness
of a PHMB-based cream in the treatment of genital
warts and the same authors suggested that PHMB can
be considered an effective therapeutic option in
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ports these preliminary results with new clinical data.
PHMB is structurally similar to naturally occurring anti-
microbial peptides (AMPs) that unlike the majority of
conventional antibiotics have the ability to enhance the
immune response by functioning as immunomodulators
[16]. Furthermore, PHMB anti-inflammatory activity has
been reported suggesting that the local action of PHMB
is probably due to the ability to inhibit the formation of
reactive oxygen species in vitro [17].
Additionally, several cell components such as integrin
α6β1, integrin α6β4 and glycosaminoglycans (GAGs)
have been proposed as primary receptors of HPV in the
cellular adhesion process [18,19]. Both integrins contain
binding sites for divalent cations (Mg2+ and Ca2+) which
are necessary for the adhesive process [20,21]. Further-
more, among the components of the MonoginW (PHMB,
EDTA, glycerol, hydroxyethyl cellulose, potassium chlor-
ide, lactic acid and water), EDTA is a strong chelating
agent which assists and enhances the action of PHMB
which interacts with the negatively charged sites dis-
placing the metallic cations essential to the integrity of
the cell outer membrane [22]. The synergistic action of
PHMB and EDTA may impair the viral adhesion process
and prevents the spread of infection [23].
In has been reported that in the in vivo infection
process the first HPV binding site is represented by the
basal membrane (BM) through an heparan sulphate pro-
teoglycan (HSPG)-dependent binding mechanism. HSPG
is a linear, highly charged, anionic polysaccharide which
belongs to the GAG family whom interaction with
macromolecules appears to be based mainly on its an-
ionic properties [24]. Because of this, it can be specu-
lated an additional site of action of PHMB which
impairs the HSPG-HPV binding in the BM counteract-
ing the viral infection process. However, the mechanism
of action of PHMB on viral adhesion is still not fully
understood and further studies are needed to clarify it.
We speculate that on the basis of combined antimicro-
bial, protective, immunomodulatory, anti-inflammatory
and chelating effects, PHMB and EDTA interact with
HPV increasing the chance to clear the infection. In our
study, this regression has been reported after three
months of treatment in 66% of patients compared to the
56% in the untreated control group. The difference be-
tween the two groups became significant after six
months suggesting a promising effect of the treatment in
the reduction of the infection persistence overtime.
The spontaneous regression rate observed in the con-
trol group is in line to the data reported in several clin-
ical studies [13].
On the basis of these preliminary results, further stud-
ies to evaluate the effects of PHMB both on cervical and
on other types of HPV infected lesions such as commonwarts in the skin, oral squamous cell carcinoma and ver-
rucous carcinoma are necessary and could provide add-
itional information on the efficacy of this molecule in
reducing the viral adhesion process.
Conclusion
In conclusion, the results obtained from this pilot study
indicate that the long term local treatment with PHMB
may represent a safe and effective approach for patients
with low- and medium-grade lesions enhancing the re-
gression rate of HPV infection. In particular, this study
suggests that a PHMB-based therapy may represent an
alternative preliminary treatment for patients with
detected HPV infection, increasing the chance to clear
the infection, avoiding the complications associated with
the conventional invasive treatments and reducing the
time exposure to HP. In order to confirm these prelim-
inary results further studies are necessary.
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